跳至主要内容
临床试验/IRCT2014120120172N1
IRCT2014120120172N1已完成4 期

Investigation of the safety and efficacy of Epolyrec on ESRD patients on hemodialysis and comparison with EPREX

otarkib Biopharmaceutical Co.0 个研究点目标入组 160 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
10 years 至 60 years(—)
性别
All

入选标准

  • Inclusion Criteria: End Stage Renal Disease patients who were under hemodialysis and had a Glomerular filtration rate less than14 ml/min/1.73m2 together with a hematocrit less than30% or hemoglobin less than 10g/dl; Presence of Iron store(serum Ferritin) more than100mg/L and transferrin saturationmore than 20%);Patients aged between 10 to 60 years

排除标准

  • CRP more than 10mg/dl; uncontrolled hypertension; Symptomatic ischemic heart disease; History of cerebrovascular event; Graft rejection; Polycystic kidney disease ; Myeloma ; Malignancies

研究者

发起方
otarkib Biopharmaceutical Co.

相似试验